Alvotech - Ordinary Shares (ALVO)

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.

ALVO stock results show that Alvotech missed on revenue for the second quarter of 2024.

Alvotech just reported results for the fourth quarter of 2023.

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.

ALVO stock results show that Alvotech missed analyst estimates for earnings per share the first quarter of 2024.

It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York.

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.